Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Journal for ImmunoTherapy of Cancer, published by the esteemed BMJ Publishing Group, is a leading scholarly journal dedicated to advancing the field of immuno-oncology. Since its inception in 2013, this Open Access journal has emerged as a pivotal platform for disseminating cutting-edge research and innovative methodologies in cancer immunotherapy. With a remarkable impact factor and stellar rankings, including Q1 listings in multiple relevant categories such as Cancer Research, Immunology, and Molecular Medicine, it plays a crucial role in bridging the gap between basic immunology and clinical applications, thus fostering collaboration among researchers, healthcare professionals, and students. The journal's scope encompasses a diverse range of topics, focusing on the latest breakthroughs and experimental findings in cancer treatment, making it indispensable for those seeking to contribute to the evolving landscape of oncological sciences. Located in the United Kingdom at the British Medical Association House, the journal continues to serve as a valuable resource for those at the forefront of cancer research and therapy.

ALLERGY is a leading international journal published by WILEY, dedicated to advancing the understanding of allergic diseases and immunology. With an ISSN of 0105-4538 and an E-ISSN of 1398-9995, this esteemed journal has been at the forefront of the field since its inception in 1948 and continues to publish high-quality research up until 2024. Positioned in the Q1 category for both Immunology and Allergy, ALLERGY ranks impressively within the top percentiles of its categories, underscoring its significant impact, as reflected in its Scopus rankings (#11 out of 233 in Immunology and Allergy, and #14 out of 236 in Immunology and Microbiology). Researchers and practitioners accessing this journal can expect a rigorous selection of peer-reviewed articles that address current challenges, innovative therapies, and advancements in the immunological sciences. Although it is not an open-access journal, ALLERGY remains vital for academics, healthcare professionals, and students alike, fostering a deeper understanding of the mechanisms and treatments associated with allergies.

JOURNAL OF IMMUNOLOGICAL METHODS, published by Elsevier, is a prominent academic journal dedicated to advancing the field of immunology through innovative methodological research. With an ISSN of 0022-1759 and E-ISSN 1872-7905, this quarterly journal has maintained a steady publication rhythm since its inception in 1971 and looks forward to continued contributions until 2024. Positioned in the Q3 quartile for both Immunology and Allergy as well as Immunology, the journal ranks #150 out of 233 in Immunology and Allergy and #164 out of 236 in Immunology and Microbiology according to Scopus metrics, indicating active engagement within its field despite its developing status. The journal aims to provide a comprehensive platform for researchers and professionals to disseminate high-quality findings, collaborate on foundational methods, and tackle the pressing challenges within immunological research, fostering a deeper understanding of immune responses and promoting advancements in allergy treatments. While it operates under a subscription model, the scholarly contributions offered within these pages are invaluable for those aiming to stay at the forefront of immunological methodologies.

Autoimmune Diseases is a leading open-access journal published by Hindawi Ltd, dedicated to advancing the understanding and treatment of autoimmune disorders. Since its inception in 2010, this journal has provided a vital platform for researchers, clinicians, and students to share innovative findings and insights from the field of immunology. With an impressive Scopus ranking that highlights its relevance, particularly in the areas of Immunology and Microbiology and Immunology and Allergy, Autoimmune Diseases occupies a key position in the scientific discourse, ranking in the top quartiles across various categories. Researchers publishing in this journal benefit from a wide audience and high visibility, reflecting the increasing importance of understanding autoimmune diseases in today’s health landscape. Accessible to all, the journal promotes collaborative research and discussion, making it an essential resource for anyone dedicated to the study and management of autoimmune conditions.

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

BIOLOGICALS, published by Academic Press Ltd - Elsevier Science Ltd, is a prestigious journal dedicated to advancing the fields of applied microbiology, biotechnology, immunology, and pharmacology. With an ISSN of 1045-1056 and E-ISSN of 1095-8320, this journal has established itself as a vital resource for researchers and practitioners, offering rigorous peer-reviewed content that spans converging disciplines from 1990 to 2024. With a commendable presence in the field, it ranks in the Q3 category across multiple domains, including applied microbiology and biotechnology, highlighting its contribution to critical advancements and knowledge dissemination. The journal's rankings reflect its relevance, with notable placements in Scopus Ranks, ensuring it remains an important platform for innovative research and discussion. Although it does not currently offer Open Access, the journal’s comprehensive review process guarantees the quality of published work, making it essential reading for professionals, academics, and students seeking to stay informed about the latest developments in biology and life sciences.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, published by Elsevier Science Inc, stands at the forefront of research in the fields of hematology and medicine, boasting an impressive ranking of #5 out of 137 in Scopus's Medicine - Hematology category, with a remarkable 96th percentile. As an essential resource for researchers, clinicians, and students, this journal, identifiable through its ISSN 1538-7933 and E-ISSN 1538-7836, encompasses pioneering studies and reviews that focus on the mechanisms of thrombosis and hemostasis, contributing significantly to advancements in patient care and therapeutic strategies. With an established presence from 2003 through 2024, it has consistently achieved a prestigious Q1 category ranking, reflecting its impactful contributions to the scientific community. Although it operates under a subscription-based model, the journal remains committed to disseminating significant findings that inform best practices in clinical settings and shape future research trajectories.

EXPERT OPINION ON BIOLOGICAL THERAPY, published by Taylor & Francis Ltd, is a prestigious journal that has been a cornerstone in the fields of Clinical Biochemistry, Drug Discovery, and Pharmacology since its inception in 2001. With an impressive impact factor reflecting Q1 status across its categories in 2023, this journal is ranked among the top in both the pharmacology and biochemistry domains, featuring in the 81st and 77th percentiles respectively. This makes it an essential resource for researchers, professionals, and students who are keen on staying at the forefront of biological therapy advancements. The journal encompasses a broad yet focused scope, providing valuable insights into innovative therapeutic strategies and drug development methodologies. Researchers benefit from the rigorous peer-review process and the opportunity to disseminate their findings to a global audience, without the constraints of open access, ensuring the integrity and prestige of published work. As it converges towards 2024, EXPERT OPINION ON BIOLOGICAL THERAPY remains an influential platform for fostering collaboration and discussion in the evolutionary landscape of biological therapies.

INTERNATIONAL REVIEWS OF IMMUNOLOGY, published by Taylor & Francis Inc, is a leading academic journal that has been a cornerstone of immunological research since its inception in 1986. With an impressive impact factor and ranked in the top quartiles of its field (Q2 in both Immunology and Allergy), this journal offers a critical platform for the dissemination of influential findings and advancements within immunology. Spanning a diverse array of topics, from basic immune mechanisms to clinical applications, it aims to support the global scientific community in enhancing immunological understanding and therapeutic interventions. Researchers and professionals alike benefit from insights provided by renowned contributors, ensuring that the journal remains relevant in a rapidly evolving field. Directly accessible through subscription or institutional access, INTERNATIONAL REVIEWS OF IMMUNOLOGY is committed to fostering collaboration and innovation, making it an essential resource for anyone involved in immunological research and practice.